News & Updates

A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.

A 23-year longitudinal follow-up in a population-based cohort has shown a slowly progressive trend in nonalcoholic fatty liver disease (NAFLD), with liver-related outcomes affecting only a small number of people, reports a recent study.

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.

Adherence to a freshwater fish-based diet helps regulate the gut microbiota and its metabolites, suggesting benefits in individuals with nonalcoholic fatty liver disease (NAFLD), reveals a study.

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

Exercise interventions may result in positive outcomes on muscular or cardiorespiratory fitness and quality of life in patients with advanced liver disease, suggest the results of a systematic review.

Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.

Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.